# The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2

Source: https://onco.cc/trials/nct07146230/  
OnCo record `nct07146230` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of durvalumab, monalizumab and oleclumab in lung cancer, run by Montefiore Medical Center, not yet recruiting.

## Summary

The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2 is a phase 2, randomised interventional study registered as NCT07146230 by Montefiore Medical Center, with a registry enrolment figure of 52 participants, started 2026-09 and due to reach its primary completion in 2028-04. Interventions recorded: Durvalumab; Monalizumab; Oleclumab; Radiotherapy. Conditions listed: Non-small Cell Lung Cancer. Primary outcome: Response rate observed using FDG-PET imaging. Lung eligibility wording from the registry: "Previously untreated, pathologically proven NSCLC and one of the following stages:". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Also known as: SPRINT 2
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07146230
- Phase: 2
- Setting: The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial 2 (SPRINT 2)
- Sponsor: Montefiore Medical Center
- Enrolled: 52

## Sources

- ClinicalTrials.gov NCT07146230: https://clinicaltrials.gov/study/NCT07146230

## Connected records

- cancers: [Unresectable stage III non-small-cell lung cancer](https://onco.cc/cancers/stage-iii-unresectable-nsclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/), [Monalizumab](https://onco.cc/drugs/monalizumab/), [Oleclumab](https://onco.cc/drugs/oleclumab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07146230.json